Do analysts rate PLYX or OPTH?

Polaryx Therapeutics currently has a consensus target price of $7.67, indicating a potential upside of 272.17%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Polaryx Therapeutics is more favorable than Optimi Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polaryx Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Optimi Health 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is PLYX or OPTH more profitable?

Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Optimi Health N/A N/A N/A

Do analysts recommend OPTH or CGTX?

Cognition Therapeutics has a consensus price target of $3.33, suggesting a potential upside of 226.80%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cognition Therapeutics is more favorable than Optimi Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Optimi Health 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is OPTH or CGTX more profitable?

Optimi Health's return on equity of 0.00% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Optimi Health N/A N/A N/A Cognition Therapeutics N/A -50.17% -40.22%

Do analysts rate PYPD or OPTH?

PolyPid presently has a consensus price target of $11.33, indicating a potential upside of 123.54%. Given PolyPid's stronger consensus rating and higher possible upside, equities research analysts clearly believe PolyPid is more favorable than Optimi Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PolyPid 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Optimi Health 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher valuation & earnings, PYPD or OPTH?

Optimi Health has higher revenue and earnings than PolyPid. Optimi Health is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PolyPid N/A N/A -$34.17M -$1.48 N/A Optimi Health $175.67K 160.69 -$1.12M -$0.76 N/A

Is PYPD or OPTH more profitable?

Optimi Health's return on equity of 0.00% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -311.08% -150.83% Optimi Health N/A N/A N/A

Is ALDX or OPTH more profitable?

Optimi Health's return on equity of 0.00% beat Aldeyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -53.14% -34.94% Optimi Health N/A N/A N/A

Do analysts rate OPTH or FBIO?

Fortress Biotech has a consensus target price of $17.00, indicating a potential upside of 513.72%. Given Fortress Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Optimi Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Optimi Health 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Fortress Biotech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Optimi Health (OPTH) Competitors

$4.93 0.00 (0.00%)

As of 08/28/2026 03:59 PM Eastern

Compare

OPTH vs. PLYX, CGTX, PYPD, ALDX, and FBIO

Should you buy Optimi Health stock or one of its competitors? Optimi Health's main competitors and comparable companies include Polaryx Therapeutics (PLYX), Cognition Therapeutics (CGTX), PolyPid (PYPD), Aldeyra Therapeutics (ALDX), and Fortress Biotech (FBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Optimi Health compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Optimi Health (NASDAQ:OPTH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Optimi Health	N/A	N/A	N/A

Polaryx Therapeutics currently has a consensus target price of $7.67, indicating a potential upside of 272.17%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Polaryx Therapeutics is more favorable than Optimi Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Optimi Health	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Polaryx Therapeutics had 1 more articles in the media than Optimi Health. MarketBeat recorded 2 mentions for Polaryx Therapeutics and 1 mentions for Optimi Health. Optimi Health's average media sentiment score of 1.87 beat Polaryx Therapeutics' score of 0.93 indicating that Optimi Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Polaryx Therapeutics	Positive
Optimi Health	Very Positive

Optimi Health has higher revenue and earnings than Polaryx Therapeutics. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Optimi Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A
Optimi Health	$175.67K	160.69	-$1.12M	-$0.76	N/A

Summary

Polaryx Therapeutics beats Optimi Health on 6 of the 10 factors compared between the two stocks.

How does Optimi Health compare to Cognition Therapeutics?

Optimi Health (NASDAQ:OPTH) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

In the previous week, Cognition Therapeutics had 2 more articles in the media than Optimi Health. MarketBeat recorded 3 mentions for Cognition Therapeutics and 1 mentions for Optimi Health. Optimi Health's average media sentiment score of 1.87 beat Cognition Therapeutics' score of 1.07 indicating that Optimi Health is being referred to more favorably in the media.

Company	Overall Sentiment
Optimi Health	Very Positive
Cognition Therapeutics	Positive

Cognition Therapeutics has a consensus price target of $3.33, suggesting a potential upside of 226.80%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cognition Therapeutics is more favorable than Optimi Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Optimi Health	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

43.3% of Cognition Therapeutics shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Optimi Health's return on equity of 0.00% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Optimi Health	N/A	N/A	N/A
Cognition Therapeutics	N/A	-50.17%	-40.22%

Optimi Health has higher revenue and earnings than Cognition Therapeutics. Optimi Health is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Optimi Health	$175.67K	160.69	-$1.12M	-$0.76	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A

Summary

Cognition Therapeutics beats Optimi Health on 8 of the 13 factors compared between the two stocks.

How does Optimi Health compare to PolyPid?

PolyPid (NASDAQ:PYPD) and Optimi Health (NASDAQ:OPTH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

PolyPid presently has a consensus price target of $11.33, indicating a potential upside of 123.54%. Given PolyPid's stronger consensus rating and higher possible upside, equities research analysts clearly believe PolyPid is more favorable than Optimi Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Optimi Health	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Optimi Health's return on equity of 0.00% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
Optimi Health	N/A	N/A	N/A

In the previous week, PolyPid had 2 more articles in the media than Optimi Health. MarketBeat recorded 3 mentions for PolyPid and 1 mentions for Optimi Health. Optimi Health's average media sentiment score of 1.87 beat PolyPid's score of 1.57 indicating that Optimi Health is being referred to more favorably in the news media.

Company	Overall Sentiment
PolyPid	Very Positive
Optimi Health	Very Positive

Optimi Health has higher revenue and earnings than PolyPid. Optimi Health is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
Optimi Health	$175.67K	160.69	-$1.12M	-$0.76	N/A

26.5% of PolyPid shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

PolyPid beats Optimi Health on 7 of the 13 factors compared between the two stocks.

How does Optimi Health compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Optimi Health (NASDAQ:OPTH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Optimi Health has higher revenue and earnings than Aldeyra Therapeutics. Optimi Health is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A
Optimi Health	$175.67K	160.69	-$1.12M	-$0.76	N/A

Aldeyra Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 270.37%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aldeyra Therapeutics is more favorable than Optimi Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Optimi Health	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Optimi Health's return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-53.14%	-34.94%
Optimi Health	N/A	N/A	N/A

In the previous week, Aldeyra Therapeutics had 1 more articles in the media than Optimi Health. MarketBeat recorded 2 mentions for Aldeyra Therapeutics and 1 mentions for Optimi Health. Optimi Health's average media sentiment score of 1.87 beat Aldeyra Therapeutics' score of 1.32 indicating that Optimi Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Aldeyra Therapeutics	Positive
Optimi Health	Very Positive

Summary

Aldeyra Therapeutics beats Optimi Health on 8 of the 13 factors compared between the two stocks.

How does Optimi Health compare to Fortress Biotech?

Optimi Health (NASDAQ:OPTH) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Fortress Biotech has a net margin of 163.32% compared to Optimi Health's net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Optimi Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Optimi Health	N/A	N/A	N/A
Fortress Biotech	163.32%	83.47%	42.98%

In the previous week, Fortress Biotech had 2 more articles in the media than Optimi Health. MarketBeat recorded 3 mentions for Fortress Biotech and 1 mentions for Optimi Health. Optimi Health's average media sentiment score of 1.87 beat Fortress Biotech's score of 0.85 indicating that Optimi Health is being referred to more favorably in the media.

Company	Overall Sentiment
Optimi Health	Very Positive
Fortress Biotech	Positive

Fortress Biotech has higher revenue and earnings than Optimi Health. Optimi Health is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Optimi Health	$175.67K	160.69	-$1.12M	-$0.76	N/A
Fortress Biotech	$63.26M	1.46	$6.82M	$2.64	1.05

Fortress Biotech has a consensus target price of $17.00, indicating a potential upside of 513.72%. Given Fortress Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Optimi Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Optimi Health	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

96.5% of Fortress Biotech shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Fortress Biotech beats Optimi Health on 13 of the 15 factors compared between the two stocks.

Get Optimi Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OPTH vs. The Competition

Export

Metric	Optimi Health	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$28.23M	$12.11B	$7.18B	$12.89B
Dividend Yield	N/A	2.62%	2.54%	11.27%
P/E Ratio	-6.49	787.65	273.17	25.45
Price / Sales	160.69	759.94	638.21	103.75
Price / Cash	N/A	15.32	28.74	36.03
Price / Book	N/A	10.49	11.08	6.36
Net Income	-$1.12M	$2.83B	$3.48B	$349.79M
7 Day Performance	-1.00%	0.58%	0.38%	-0.40%
1 Month Performance	1.65%	5.69%	7.89%	4.24%
1 Year Performance	N/A	6.19%	24.71%	15.13%

Optimi Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OPTH Optimi Health	1.5616 of 5 stars	$4.93 flat	N/A	N/A	$28.23M	$175.67K	N/A	N/A	Positive News
PLYX Polaryx Therapeutics	2.9279 of 5 stars	$2.11 +1.0%	$7.67 +263.3%	N/A	$104.18M	N/A	N/A	11	Gap Up
CGTX Cognition Therapeutics	2.5794 of 5 stars	$1.06 +1.0%	$3.33 +214.5%	-58.0%	$99.85M	N/A	N/A	20	Positive News
PYPD PolyPid	3.2097 of 5 stars	$5.12 +0.2%	$11.33 +121.4%	+51.3%	$97.51M	N/A	N/A	80	Short Interest Decrease
ALDX Aldeyra Therapeutics	3.4165 of 5 stars	$1.54 -1.3%	$5.50 +257.1%	-74.6%	$94.11M	N/A	N/A	10	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OPTH) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Optimi Health (OPTH) Competitors

OPTH vs. PLYX, CGTX, PYPD, ALDX, and FBIO

How does Optimi Health compare to Polaryx Therapeutics?

Summary

How does Optimi Health compare to Cognition Therapeutics?

Summary

How does Optimi Health compare to PolyPid?

Summary

How does Optimi Health compare to Aldeyra Therapeutics?

Summary

How does Optimi Health compare to Fortress Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPTH vs. The Competition

Optimi Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Optimi Health (OPTH) Competitors

OPTH vs. PLYX, CGTX, PYPD, ALDX, and FBIO

How does Optimi Health compare to Polaryx Therapeutics?

Is PLYX or OPTH more profitable?

Do analysts rate PLYX or OPTH?

Does the media favor PLYX or OPTH?

Which has higher earnings & valuation, PLYX or OPTH?

Summary

How does Optimi Health compare to Cognition Therapeutics?

Does the media refer more to OPTH or CGTX?

Do analysts recommend OPTH or CGTX?

Do institutionals and insiders hold more shares of OPTH or CGTX?

Is OPTH or CGTX more profitable?

Which has preferable valuation and earnings, OPTH or CGTX?

Summary

How does Optimi Health compare to PolyPid?

Do analysts rate PYPD or OPTH?

Is PYPD or OPTH more profitable?

Does the media favor PYPD or OPTH?

Which has higher valuation & earnings, PYPD or OPTH?

Do institutionals & insiders believe in PYPD or OPTH?

Summary

How does Optimi Health compare to Aldeyra Therapeutics?

Do insiders & institutionals hold more shares of ALDX or OPTH?

Which has preferable valuation and earnings, ALDX or OPTH?

Do analysts prefer ALDX or OPTH?

Is ALDX or OPTH more profitable?

Does the media refer more to ALDX or OPTH?

Summary

How does Optimi Health compare to Fortress Biotech?

Is OPTH or FBIO more profitable?

Does the media favor OPTH or FBIO?

Which has higher valuation & earnings, OPTH or FBIO?

Do analysts rate OPTH or FBIO?

Do insiders and institutionals have more ownership in OPTH or FBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPTH vs. The Competition

Optimi Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools